<DOC>
	<DOCNO>NCT00620698</DOCNO>
	<brief_summary>Trials evaluate new therapy stop slow progression ALS depend critically upon use outcome measure ass whether potential treatment effective . The effective outcome measure , few patient need enrol short trial . Many outcome measure use year , include strength assessment , breathe test , functional status survey , nerve testing , far ideal . A new method , call electrical impedance myography ( EIM ) appear especially promising provide consistent data one test session next , sensitive muscle deterioration occur ALS , entirely painless non-invasive . In study , investigator multiple institution plan compare several different outcome measure , include EIM , approximately 120 ALS patient , patient follow period one year . All measure compare one another assessment ability detect disease progression make . Our goal determine whether EIM serve valuable new outcome measure , ultimately lead substantially faster , effective ALS trial require few patient .</brief_summary>
	<brief_title>Electrical Impedance Myography Outcome Measure Amyotrophic Lateral Sclerosis Clinical Trials</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Definite probably ALS El Escorial criterion Muscle strength 3.5 one limb Forced vital capacity le 70 % Atypical form motor neuron disease ( monomelic amyotrophy , primary lateral sclerosis ) Pacemaker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>motor neuron disease</keyword>
	<keyword>outcome measure</keyword>
	<keyword>biomarker</keyword>
	<keyword>impedance</keyword>
</DOC>